Modulation of mismatch repair and genomic stability by miR-155

Nicola Valeri(University of Ferrara), Pierluigi Gasparini(The Ohio State University Wexner Medical Center), Muller Fabbri(The Ohio State University Wexner Medical Center), Chiara Braconi(The Ohio State University Wexner Medical Center), Angelo Veronese(The Ohio State University Wexner Medical Center), Francesca Lovat(The Ohio State University Wexner Medical Center), Brett Adair(The Ohio State University Wexner Medical Center), Ivan Vannini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Francesca Fanini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Arianna Bottoni(The Ohio State University Wexner Medical Center), Stefan Costinean(The Ohio State University Wexner Medical Center), Sukhinder K. Sandhu(The Ohio State University Wexner Medical Center), Gerard J. Nuovo(The Ohio State University Wexner Medical Center), Hansjüerg Alder(The Ohio State University Wexner Medical Center), Roberta Gafà(University of Ferrara), Federica Calore(The Ohio State University Wexner Medical Center), Manuela Ferracin(University of Ferrara), Giovanni Lanza(University of Ferrara), Stefano Volinia(University of Ferrara), Massimo Negrini(University of Ferrara), Michael A. McIlhatton(The Ohio State University Wexner Medical Center), Dino Amadori(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Richard Fishel(The Ohio State University Wexner Medical Center), Carlo M. Croce(University of Ferrara)
Proceedings of the National Academy of Sciences
March 29, 2010
Cited by 350Open Access
Full Text

Abstract

Inactivation of mismatch repair (MMR) is the cause of the common cancer predisposition disorder Lynch syndrome (LS), also known as hereditary nonpolyposis colorectal cancer (HNPCC), as well as 10-40% of sporadic colorectal, endometrial, ovarian, gastric, and urothelial cancers. Elevated mutation rates (mutator phenotype), including simple repeat instability [microsatellite instability (MSI)] are a signature of MMR defects. MicroRNAs (miRs) have been implicated in the control of critical cellular pathways involved in development and cancer. Here we show that overexpression of miR-155 significantly down-regulates the core MMR proteins, hMSH2, hMSH6, and hMLH1, inducing a mutator phenotype and MSI. An inverse correlation between the expression of miR-155 and the expression of MLH1 or MSH2 proteins was found in human colorectal cancer. Finally, a number of MSI tumors with unknown cause of MMR inactivation displayed miR-155 overexpression. These data provide support for miR-155 modulation of MMR as a mechanism of cancer pathogenesis.


Related Papers